在COVID-19疫苗接种后区分轴状淋巴腺病与恶性淋巴腺病
Shintaro Yamanaka1, Keiko Tanaka2, Masao Miyagawa3
1Department of Clinical Oncology, Ehime University Graduate School of Medicine, Toon 791-0295, Japan.
Journal of clinical medicine
|June 27, 2024
概括
恶性超代谢性淋巴腺病变 (MHL) 和COVID-19疫苗相关淋巴腺病变 (VAHL) 可以使用成像特征进行区分. 淋巴结的特征,如小轴长度和圆度,特别是在没有脂肪的节点中,即使在接种疫苗后,也有助于识别恶性瘤.
科学领域:
- 放射学 放射学是一门学科.
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 在接种COVID-19疫苗后,轴心淋巴腺病也可能发生.
- 区分疫苗相关淋巴腺症与恶性超代谢性淋巴腺症对于患者管理至关重要.
研究的目的:
- 使用临床成像来区分恶性高代谢关节淋巴腺症 (MHL) 和与COVID-19疫苗相关的关节高代谢淋巴腺症 (VAHL).
- 为了确定可预测股淋巴腺瘤疫苗接种后患者恶性瘤的成像特征.
主要方法:
- 对1096名患者进行了正子发射断层扫描-计算机断层扫描 (PET-CT).
- 188名接种疫苗后支淋巴腺病患者被分析并分为VAHL,MHL和模两可的组.
- 使用声谱,CT和18F-FDG PET,对淋巴结胀的统计分析.
主要成果:
- 恶性超代谢性淋巴腺病变 (MHL) 主要影响女性,并与乳腺癌有关.
- 与VAHL和模两可的病例不同,MHL病例缺乏淋巴结脂肪.
- 轴心淋巴结小轴长度,圆度,SUVmax和组织与背景比率 (TBR) 是MHL的显著预测因素.
结论:
- 轴心淋巴结小轴和没有脂肪的节点的圆性可以表明对恶性瘤的怀疑,即使在COVID-19疫苗接种后.
- 18F-FDG PET成像建议在可疑情况下进行进一步评估.
相关概念视频
01:51Vaccinations
44.4K
Overview
44.4K
01:30Cancer Vaccines
351
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
351